RNAi and RNA Reagents

Control products, reagents, and RNA samples for use in the study of RNA and the process of RNA interference (RNAi or post-transcriptional gene silencing).

601 – 615 of 2,672 results

601

HORIZON DISCOVERY BIOSCIENCES LIMITED ON-TARGETPLUS SIRNA 6424

NC3875072 ON-TARGETPLUS SIRNA 6424

Pricing & Availability

602

HORIZON DISCOVERY BIOSCIENCES LIMITED ACCELL HU MB21D1 SIRNA

Accell Hu MB21D1 siRNA

Pricing & Availability

603

HORIZON DISCOVERY BIOSCIENCES LIMITED ON-TARGET HUM SMARCD1 6602 5NM

NC3874735 ON-TARGET HUM SMARCD1 6602 5NM

Pricing & Availability

604

HORIZON DISCOVERY BIOSCIENCES LIMITED HSD17B13 SIRNA 5NMOL

SMARTpool: ON-TARGETplus HSD17B13 siRNA 5nmol

Pricing & Availability

605

Gene Link Inc CUSTOM SIRNA STD PUR 10 NMOLS

NC3831743 CUSTOM SIRNA STD PUR 10 NMOLS

Pricing & Availability

606

HERA BIOLABS SUPER PIGGYBAC TRANSPOS MRNA

NC2081716 SUPER PIGGYBAC TRANSPOS MRNA

Pricing & Availability

607

HORIZON DISCOVERY BIOSCIENCES LIMITED ONTARGET HUM MAP2K7 5609 5NMOL

NC3874729 ONTARGET HUM MAP2K7 5609 5NMOL

Pricing & Availability

608

HORIZON DISCOVERY BIOSCIENCES LIMITED 10 NMOL SET OF 4 HCN2 ACCELL S

NC3780989 10 NMOL SET OF 4 HCN2 ACCELL S

Pricing & Availability

609

Genscript Corporation CD37 hFc Chimera Human

CD37 is a tetraspanin expressed prominently on the surface of B cells It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia Currently several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials Given the unique role of CD37 in the biology of B cells it seems that CD37 constitutes more than a docking point for monoclonal antibodies and targeting this molecule may provide additional benefit to relapsed or refractory patients